Muscular dystrophy limb-girdle with delta-sarcoglyan deficiency

Muscular Dystrophy Limb-Girdle with Delta-Sarcoglycan Deficiency is a subtype of Limb-Girdle Muscular Dystrophy (LGMD), a group of genetic disorders characterized by progressive muscle weakness and atrophy, particularly affecting the muscles around the hips and shoulders (the limb-girdle area). This specific form of LGMD is caused by a deficiency in the delta-sarcoglycan protein, due to mutations in the gene responsible for its production.

Overview

Muscular dystrophies are a diverse group of genetic diseases that cause progressive weakness and degeneration of the skeletal muscles. Limb-girdle muscular dystrophy encompasses a subset of these disorders, each associated with specific genetic mutations. The delta-sarcoglycan deficiency in LGMD results from mutations in the SGCD gene, which encodes the delta-sarcoglycan protein, a crucial component of the dystrophin-glycoprotein complex. This complex strengthens muscle fibers and protects them from injury during contraction.

Symptoms

The symptoms of LGMD with delta-sarcoglycan deficiency typically manifest in childhood to early adulthood and may include:

• Muscle weakness, particularly in the shoulders and hips
• Difficulty walking, running, and climbing stairs
• Muscle wasting in the affected areas
• Increased risk of cardiac issues, due to the role of delta-sarcoglycan in heart muscle

Diagnosis

Diagnosis of LGMD with delta-sarcoglycan deficiency involves a combination of clinical evaluation, family history, genetic testing, and muscle biopsy. Genetic testing can confirm the presence of mutations in the SGCD gene, while muscle biopsy may show reduced or absent delta-sarcoglycan protein in muscle tissues.

Treatment

There is currently no cure for LGMD with delta-sarcoglycan deficiency. Treatment focuses on managing symptoms and improving quality of life. This may include:

• Physical therapy to maintain muscle strength and flexibility
• Use of assistive devices such as braces or wheelchairs
• Regular cardiac monitoring
• Medications to manage cardiac symptoms

Prognosis

The prognosis for individuals with LGMD with delta-sarcoglycan deficiency varies. While the condition tends to progress slowly, the degree of muscle weakness and cardiac involvement can significantly impact life expectancy and quality of life.

Research

Research into LGMD with delta-sarcoglycan deficiency is ongoing, with efforts focused on understanding the genetic mechanisms underlying the disease and developing gene therapy and other treatments to target these mechanisms.

Muscular dystrophy limb-girdle with delta-sarcoglyan deficiency Resources
Latest articles Most recent articles Ongoing trials	Wikipedia